NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality (not requiring hospitalization). NRX-101 is a patented, fixed dose combination product…